Ingevity (NGVT) reported Q1 adjusted earnings late Monday of $0.99 per diluted share, up from $0.47 a year earlier.
Four analysts polled by FactSet expected $0.74.
Revenue for the quarter ended March 31 was $284 million, down from $340.1 million a year earlier.
Three analysts surveyed by FactSet expected $285.5 million.
Widening the bottom end of its guidance, the company now expects full-year 2025 sales of between $1.25 billion and $1.40 billion, compared with the $1.30 billion to $1.40 billion range set out in February. Analysts polled by FactSet expect $1.36 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。